More recently, several therapies targeting select mutations, including IDH1 (ivosidenib) (3), IDH2 (enasidenib) (4), and FLT3 (gilteritinib) (5), have been approved for AML treatment and demonstrate a unique differentiating phenotype. Here, FLT3 is linked to acute myeloid leukemia.